BioDuro is a US company founded in 1996, and headquartered in Irvine, California. With more than 2,000+ scientists, we have 7 R&D and manufacturing campuses across the US and China. We offer fully integrated CRDMO services from discovery to commercial manufacturing across medicinal chemistry, biology, DMPK, drug substance and drug product, including multiple modalities small molecules, peptides, oligonucleotides and antibody drug conjugates.
We leverage our broad capabilities and unique technology platforms to empower biotech and pharmaceutical partners worldwide. Our integrated approaches accelerate and de-risk new drug discovery and development, creating higher value outcomes for our clients. Committed to the highest standards of compliance and business operations, we maintain a science-driven, customer-oriented, innovative and people-focused culture.
As a pure-play CRDMO, BioDuro operates under one global standard, providing integrated, fast, and flexible services to meet the unique needs of our clients and accelerate development timelines.
We leverage our broad capabilities and unique technology platforms to empower biotech and pharmaceutical partners worldwide. Our integrated approaches accelerate and de-risk new drug discovery and development, creating higher value outcomes for our clients. Committed to the highest standards of compliance and business operations, we maintain a science-driven, customer-oriented, innovative and people-focused culture.
As a pure-play CRDMO, BioDuro operates under one global standard, providing integrated, fast, and flexible services to meet the unique needs of our clients and accelerate development timelines.
Biofidelity’s mission is to improve and extend cancer patients’ lives by enabling better targeting of therapies, early detection of treatment resistance, and routine monitoring of treatment response. Our unique technology is designed to allow rapid, broad adoption of our assays in testing labs around the world, enabling a step change in patient care.
No data available
No data available
The Greater Munich Area is the location of a longstanding, unique network of a strong Life Science industry, scientific institutions and clinics – a network coordinated by BioM Biotech Cluster Development GmbH (BioM). BioM also manages the Bavarian Biotech Cluster of all life science regions in Bavaria. Altogether, 320 life science companies are located in the Greater Munich Area, in Regensburg and Würzburg.. . BioM is a publicly funded service and consulting company with the aim to promote the development of the Munich Biotech Cluster as an internationally renowned centre of excellence in the field of innovative biotechnology and to link its work closely with the other Bavarian biotech regions. BioM supports local biotech start-up companies with a wide variety of services and training tools. Through the network of all important stakeholders in the region, BioM assists Bavarian-based companies in finding the right contacts and partners, also with regards to international markets.
Founded in 2004, BioMed Realty Trust, Inc. (NYSE: BMR; https://www.biomedrealty.com) delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities in the life science industry. Currently, the company has over $5 billion invested in the state-of-the-art research facilities representing more than 13 million square feet across the United States and the United Kingdom.
Cambridge Epigenetix’s mission is to harness the power of epigenetics to develop the next generation of diagnostics and therapeutics. . . Epigenetics has the potential to improve human health though the earlier diagnosis, improved patient stratification and the development of more effective, targeted therapies. Importantly, epigenetic modifications are also reversible, allowing physicians to identify and suggest lifestyle changes that are most beneficial for preventing disease. . . We are currently applying our disruptive epigenetics discovery platform and know-how to biomarker and clinical assay development programmes for a number of diseases with significant unmet need — both internally and in partnership with leading biopharma companies.
BioNJ, The Gateway to Health, is a powerful network of 400 Member Investors representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait, BioNJ is committed to the growth and prosperity of New Jersey’s life sciences ecosystem to help accelerate the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society. As the industry’s voice in New Jersey, we fulfill our Mission to help our Members help Patients by driving capital formation and fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit https://www.BioNJ.org
Bionow is the membership organisation supplying support and services to the life-sciences industry for the North and beyond. We offer a range of specialist business support products and services such as events, training, recruitment and other services. All are aimed at enabling the potential of life science and biotech businesses and making them more competitive.
Bionow supports business growth, competitiveness and innovation within the biotech and life science sectors across the Northern half of the UK. Our membership services add value and cost-efficiency to scientific, clinical and business operations within early stage and growth-oriented firms.
Our membership base ranges from start-ups and SMEs to large global organisations. Bionow's membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses.
Bionow supports business growth, competitiveness and innovation within the biotech and life science sectors across the Northern half of the UK. Our membership services add value and cost-efficiency to scientific, clinical and business operations within early stage and growth-oriented firms.
Our membership base ranges from start-ups and SMEs to large global organisations. Bionow's membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses.
BioPartner UK is the independent, accredited trade organisation that promotes international partnering for trade, investment and collaborations with UK life science enterprises. BioPartner’s UK Delegations promote the UK presence at international conferences. We work with conference organisers, in-country agencies and overseas networks to provide the best business opportunities for our members and UK companies travelling with outward delegations. BioPartner also provides access to government grants and entry fee discounts for all UK-based organisations.